Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.